Leading the Way in Effective Drug Development
Neuropathic Pain Trials Combine Drug Adherence, E-Diaries for Personalized Interventions
The percentage of people in pain around the world rose from 26.3% in 2009 to 32.1% in 2021, an increase of approximately 500 million people. Persistent pain in the U.S. is estimated to affect over 100 million adults at any given time, and carries direct and indirect costs of over $600 billion annually.
Psoriasis Clinical Trials Aim to Improve Disease Management, Drug Adherence
Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. This blog provides a brief overview of medication adherence in psoriasis, a snapshot of the psoriasis clinical trial landscape, and a look at technology used to improve dosing performance in psoriasis clinical research.
Clinical Trials in Chronic Hepatitis B Look To Optimize Dose, Regimen For Tolerable Immune Activation
Chronic hepatitis B virus (HBV) infection affects about 296 million people globally and is the leading worldwide cause of cirrhosis and liver cancer.
The Future of Anti-Obesity Medications: Clinical Trials and Adherence Challenges
The prevalence of obesity has been steadily increasing worldwide, leading to a growing demand for effective anti-obesity medications. In recent years, clinical trials have focused on developing new drugs with better efficacy and safety profiles.
Medication Adherence Tech and Predictive Analytics Support Patient Retention in Schizophrenia Clinical Trials
The rising prevalence of Central Nervous System (CNS) disorders due to a growing population and aging society has resulted in a major unmet health need. CNS drug development has stagnated in some areas despite concerted effort over the past few decades.
How Predictive Drug Adherence Can Forecast Patient Dropout in Asthma Clinical Trials
Poor medication adherence has a significant impact on the viability of asthma clinical trials. Inhaled corticosteroids, for instance, have an adherence rate of ∼50%, according to a systematic review of 51 observational studies.